Dermaseb

Quick links to important sections

Dermaseb

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dermaseb

Quick Facts

Property Description
Active ingredient Sulfacetamide (or Sulfacetamide Sodium)
Form Topical (Cream, Lotion, Gel, Cleanser) or Ophthalmic Solution
Pharmacological class Sulfonamide Antibiotic, Anti-infective Agent
General purpose To control bacterial proliferation and mitigate inflammation
Origin Synthetic (derived from sulfanilamide)

What Type of Medicine is Dermaseb?

Dermaseb is a prescription-only topical pharmaceutical preparation that utilizes Sulfacetamide as the core active ingredient. It belongs to the sulfonamide antibiotic class of drugs, classifying it as a synthetic anti-infective agent. This identity as a sulfa drug establishes its function as a bacteriostatic agent designed for external use. Sulfacetamide is clinically recognized for its effectiveness against a variety of organisms commonly associated with secondary cutaneous infections, supporting its role in dermatologic and ophthalmic care. The drug's mechanism is highly targeted, aiming specifically to restrict bacterial growth pathways.


Composition, Forms, and General Purpose

The synthetic nature of Sulfacetamide means it is chemically derived from sulfanilamide. Dermaseb, the medicinal entity, is available in various pharmaceutical preparations, including a cream, lotion, gel, or cleanser for topical (cutaneous) administration, and as a sterile aqueous solution for ophthalmic (ocular) administration. This versatility is a key differentiating factor, allowing it to address bacterial issues both on the skin and the ocular surface. While often used as a single active ingredient product, many topical versions are formulated as combination products by adding Sulfur. This addition leverages the combined action of the bacteriostatic Sulfacetamide and the keratolytic effect of Sulfur to improve the management of skin conditions. The general purpose is to serve as a topical antibacterial agent that effectively limits bacterial proliferation and helps manage associated inflammation.

Regulatory References

  1. DailyMed - Sulfacetamide Sodium Ophthalmic Solution
  2. MedlinePlus Drug Information - Sulfacetamide Ophthalmic

What side effects are possible with Dermaseb?

Possible side effects and safety information

The safety profile of Sulfacetamide, the active ingredient in Dermaseb, is characterized by its sulfonamide class, requiring regulatory documentation of both common local reactions and rare, severe systemic events. The following information is based strictly on government regulatory documents.

Adverse Reaction Scope

Category Description
Common Local Effects Burning, stinging, irritation, redness (erythema), and itching (pruritus) at the site of application are frequently noted with both topical and ophthalmic use.
System-Organ Classes Adverse reactions are primarily classified as Skin and Subcutaneous Tissue Disorders (dermatological), Ocular Disorders, and, rarely, Blood and Lymphatic System Disorders (hematologic).
Serious Adverse Reactions Regulatory documents for sulfonamides include the risk of rare, severe systemic reactions, such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Aplastic Anemia.

Safety Considerations and Restrictions

Official labeling defines specific safety limitations. The medicine is restricted for use in individuals with a known history of sulfonamide (sulfa) allergy due to the high risk of cross-sensitivity. This drug also has documented potential for cross-sensitivity with other chemically related agents, including thiazides and sulfonylureas.

Furthermore, the regulatory text documents the risk of photosensitivity (increased skin sensitivity to sunlight) during treatment duration. The systemic risk of the sulfonamide class must be acknowledged even when the drug is applied topically, as absorption may occur.

This structure allows the official safety profile to communicate the full spectrum of possible outcomes, from frequent local complaints to rare, exceptional systemic events.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Sulfacetamide Sodium overdose is primarily concerned with systemic toxicity following large oral overdosage or accidental ingestion, as topical ophthalmic overdosage is generally stated not to cause acute problems.

Documented Overdose Presentations

Regulatory documents state that overdosage may present with gastrointestinal symptoms such as Nausea and Vomiting. The most serious officially documented manifestations are linked to the urinary and renal systems. These include Hematuria (blood in urine) and Crystalluria (crystals in urine), which are caused by the precipitation of sulfa crystals in the renal tubules.

Serious Outcomes and Emergency Action

The precipitation of sulfa crystals can lead to the severe, life-threatening systemic outcome of Renal shutdown (acute kidney failure). Due to this potential severity, regulatory authorities mandate that emergency treatment should be started immediately in the event of any suspected overdosage.

Immediate professional guidance is required. Individuals are instructed to contact their local Poison Control Center or a doctor for management. Treatment is officially defined as symptomatic and supportive, and procedural steps such as gastric aspiration and lavage may be considered for recent oral ingestion. The risk of Renal shutdown is a particular consideration for individuals with pre-existing kidney disease.

Therapeutic Uses of Dermaseb

Dermaseb is generally applied across domains where additional symptomatic support is needed, helping to address symptoms related to inflammatory or irritative states. It plays a role in managing several skin and eye conditions.

The medication is commonly used to help with conditions characterized by periods of heightened symptoms, including acne vulgaris, papulopustular rosacea, seborrheic dermatitis, and acute bacterial conjunctivitis. In these scenarios, it is relevant for managing symptom clusters that may become intense or disruptive, such as inflamed lesions, excessive scaling, and discharge.

The core therapeutic focus is on providing supportive relief when symptoms interfere with daily functioning, which may help patients cope more steadily with symptom fluctuations. It is often used during phases when symptoms become more noticeable, where it may be part of symptomatic management to help address physical discomfort. The focus is on providing supportive relief when symptoms interfere with routine activities.


Quick Fact: Management of Inflammatory Skin & Eye Symptoms

Symptom Axis Therapeutic Focus
Facial Dermatoses Addressing redness and symptoms related to inflammatory or irritative states.
Seborrheic Flaring Supports the handling of scaling, flaking, and irritation.
Acute Ocular Relevant for easing bacterial discharge and redness.

Regulatory References

  1. National Library of Medicine (NIH) DailyMed Label

Eligibility and Restrictions for Use

Who can and cannot use Dermaseb?

The official eligibility profile for Dermaseb (Sulfacetamide) is determined by absolute contraindications and population-specific restrictions documented in regulatory labeling.

Contraindicated Populations

Dermaseb must not be used by specific patient groups, as its use is formally contraindicated by regulatory authorities:

  • Patients with a known history of hypersensitivity to sulfonamides (sulfa allergy) or any other component in the formulation.
  • Patients with documented kidney disease (renal impairment).

Restricted and Conditional Use

Use of Dermaseb is limited or requires special consideration in certain populations where safety and efficacy data are not fully established or systemic risk is increased:

Population Group Regulatory Status Restriction/Caution
Children under 12 years Use Not Established Safety and effectiveness have not been established for topical use.
Pregnant Women Conditional Use (Category C) Should be used only if clearly needed and potential benefits outweigh risks.
Nursing Mothers Caution Required Must be used with caution, as systemic sulfonamides may carry risk during lactation.

Eligibility is typically established for adults and adolescents (12 years and older) for approved topical indications. Additional caution is advised when applying the product to denuded or abraded skin due to increased risk of systemic absorption.

What should I know about interactions with other medicines?

Dermaseb Interactions with other medicines and products

The official interaction profile for topical and ophthalmic Sulfacetamide (Dermaseb) is primarily defined by its limited systemic exposure, as documented in regulatory sources. This profile identifies specific circumstances and substances that may interact with the drug or affect its concentration in the body.

Interactions Requiring Co-Administration Restrictions

Co-administration is restricted with specific metallic agents. Sulfacetamide formulations are chemically incompatible with silver preparations, such as silver nitrate, and must not be used concurrently. This is a direct physical or chemical interaction, not a metabolic one.

Factors Affecting Systemic Drug Exposure

The systemic exposure of the sulfonamide component is influenced by the condition and extent of the application site. Regulatory documents note that absorption is greater when the product is applied to large, infected, abraded, denuded, or severely burned areas. This condition-dependent factor can lead to higher systemic concentrations of the drug.

Population-Specific Interaction Notes

Due to the reliance on renal elimination for absorbed sulfonamide, use in certain populations requires specific consideration for clearance. Patients with renal impairment or kidney disease are noted to face a risk of drug accumulation of the absorbed compound and its metabolites, a population-specific factor that affects systemic exposure and potential adverse risk.

Mechanism of Action

How Dermaseb Works

Dermaseb exerts its pharmacodynamic activity through two primary mechanistic domains, modulating both microbial essential processes and host inflammatory signaling pathways. The action initiates at the cellular level, leading to adjustment within targeted physiological processes.

Antagonism of Microbial Folate Synthesis

This domain involves the inhibition of a key microbial metabolic pathway. Dermaseb functions as a competitive antagonist of para-aminobenzoic acid (PABA), directly interfering with the dihydropteroate synthase enzyme. This mechanism restricts the synthesis of bacterial folic acid, modifying early molecular steps essential for microbial nucleic acid synthesis and subsequent proliferation.

Modulation of Inflammatory Mediator Cascades

The second domain relates to adjusting signaling pathways within the host's tissue. Dermaseb modulates processes driven by distinct intracellular signaling patterns, including those involving NF-mathbfkappax000BB and mTORC1. Furthermore, it alters the activity of intermediaries such as the antimicrobial peptide cathelicidin. This results in the modification of inflammatory mediator cascades within the skin's biological response systems, influencing downstream cellular communication.

Dosage and Administration Information

Dermaseb, which utilizes sulfacetamide sodium as the active component, is administered via two primary official routes: topical (cutaneous) for skin preparations and ophthalmic (ocular) for preparations intended for the eye. The route of administration is explicitly determined by the product form, and topical preparations are strictly labeled as not for ophthalmic use.

For dermatologic use, the medicine is available in various forms, including cleansers, lotions, and creams. Lotions and creams are typically applied as a thin film to the affected area once or twice daily. If the preparation is a suspension or lotion, it must be shaken well before use. Cleanser forms require massaging into the skin for 10 to 20 seconds before rinsing thoroughly, which is a key procedural instruction.

The standard duration of use is typically a short course of 8 to 10 days for acute episodes of secondary bacterial infection. For managing chronic conditions, the frequency may be reduced to once or twice weekly for maintenance.

Ophthalmic preparations are applied by instilling one or two drops into the conjunctival sac. The usual dosing frequency for acute ocular conditions is every two to three hours, with the interval lengthening as the condition responds. A critical handling constraint for ophthalmic solutions is the requirement to discard the product if it darkens in color upon standing. Furthermore, use is not established for topical forms in children under 12 years of age or for ophthalmic forms in infants younger than two months. The medicine is not to be used by patients with kidney disease.

Recent Clinical Evidence

Research evidence / Overview of studies for Dermaseb


Evidence for Topical Use in Inflammatory Skin Conditions

This section summarizes the research designs and populations used to evaluate Dermaseb for common facial dermatoses, outlining what types of studies exist and what specific clinical changes they were designed to measure. Research often includes its use as a combination product with Sulfur.

Clinical Research on Papulopustular Rosacea

Research for short-term symptom changes in rosacea included randomized controlled trials (RCTs) against a vehicle (an inactive agent). Studies monitored lesion counts and reported how symptoms evolved in the observed populations, with data were recorded related to the comparison with the vehicle group. Comparative evidence against other established topical treatments for rosacea remains limited, and some findings were not derived from the highest quality study designs. Research provides context on short-term changes, but long-term effects are not fully established.

Studies Evaluating Acne Vulgaris

The research base for the topical agent in acne vulgaris includes observational studies and case series. Studies monitored outcomes related to physical discomfort and inflammatory states, recording changes in mean inflammatory and non-inflammatory lesion counts. Findings describe patterns observed in the studies and report how symptoms evolved in the observed populations. Evidence quality varies across studies, and research exploring the agent’s use when applied alone has a smaller base compared to studies for other topical agents.


Evidence for Ophthalmic Use in Acute Bacterial Conjunctivitis

Research for the ophthalmic formulation includes comparative randomized controlled trials. These trials were conducted during periods of increased symptom activity. Studies monitored outcomes describing episodic or acute changes, such as the rate of clinical cure and the rate of microbiologic cure (pathogen eradication). Systematic reviews note that findings often did not describe a clear pattern of difference in outcomes when this agent was evaluated alongside other broad-spectrum topical antibiotics used for this condition. The research highlights what is known, but data show patterns related to the presence of resistance in certain bacterial isolates.


What is Still Uncertain About the Research Evidence

The available evidence highlights what is known — and what is still uncertain — about the agent's research base. Evidence quality varies across studies, with a reliance on observational studies for some indications. Findings were mixed regarding research exploring the agent's study findings related to persistent background redness in rosacea. There is limited information for long-term outcomes across all indications, and comparative evidence is lacking or inconsistent against certain newer standard treatments.

Key Studies & References

  1. Sulfacetamide Sodium and Sulfur Topical Suspension Labeling Information (DailyMed)
  2. The Use of Sodium Sulfacetamide in Dermatology
  3. Combination Sodium Sulfacetamide 10% and Sulfur 5% Cream With Sunscreens Versus Metronidazole 0.75% Cream for Rosacea
  4. Topical antibiotics for acute bacterial conjunctivitis: a systematic review
  5. Ophthalmic Antibiotics Therapeutic Class Review

Frequently Asked Questions (FAQ)

Common questions about Dermaseb (FAQ)

Q: Can Dermaseb be used on sensitive skin areas, like the face or groin?

A: Official instructions indicate the product is applied as a thin film to the affected area. Regulatory sources do not list specific anatomical restrictions on general use areas like the face or groin. However, official information does note that systemic absorption is greater when the product is applied to large, abraded, denuded, or severely burned skin areas.

Q: What is the difference between Dermaseb and other common anti-fungal creams?

A: According to the official product information, Dermaseb's active ingredient, sulfacetamide, classifies it as a sulfonamide antibiotic and an anti-infective agent. This identity makes it an antibacterial and bacteriostatic medicine, which is distinct from creams whose primary purpose is to treat fungal infections.

Q: Are there any special warnings for people with liver or kidney issues when using Dermaseb?

A: Regulatory documents formally contraindicate the use of Dermaseb in patients with documented kidney disease (renal impairment) because of the risk that the absorbed compound may accumulate in the body. Official labeling does not include specific warnings regarding liver issues.

Q: Is Dermaseb safe to use during pregnancy or while breastfeeding, according to official sources?

A: Official sources assign a Conditional Use (Category C) status during pregnancy. The official documentation indicates the drug is to be used only if clearly needed and potential benefits outweigh risks. Official documentation indicates caution is advised during lactation, as the sulfonamide component carries potential risk.

Q: Can children or teenagers use Dermaseb?

A: Official documents state that the safety and effectiveness of the topical forms have not been established in children under 12 years of age. The approved topical indications typically establish eligibility for adults and adolescents (12 years and older) for the approved indications.

Q: Can using Dermaseb make my skin more sensitive to the sun?

A: Regulatory labeling documents the risk of photosensitivity during treatment duration. Photosensitivity is an increased skin sensitivity to sunlight.

Q: Is Dermaseb safe to use with other skin treatments, like hydrocortisone cream?

A: Official regulatory documents list silver preparations as chemically incompatible with Dermaseb. While other drug-to-drug interactions are noted, the official interaction profile does not explicitly mention specific interactions with hydrocortisone cream or other topical corticosteroids.

Q: Is it possible for the fungus to become resistant to Dermaseb over time?

A: Dermaseb is an antibacterial agent, and its mechanism of action is related to bacterial processes, not fungal ones. Regulatory research notes patterns related to the presence of resistance in certain bacterial isolates that the drug is designed to control.

Q: Is Dermaseb available without a prescription in some places?

A: According to official product information, Dermaseb is defined as a prescription-only topical pharmaceutical preparation in the jurisdictions covered by the regulatory labeling.

Q: Why do some people say Dermaseb is for dandruff, but others say it's for fungal infections?

A: Dermaseb is formally classified as an anti-infective, bacteriostatic agent used to control bacterial issues and mitigate inflammation. Topical versions are often formulated as combination products with Sulfur to manage inflammatory skin conditions, which may lead to confusion regarding the specific condition it addresses.

Q: Do I have to use Dermaseb for a specific number of days, even if my symptoms clear up?

A: Official labeling establishes the standard duration of use as typically a short course of 8 to 10 days for acute episodes. This duration is described in regulatory documents for the treatment of acute conditions.

Q: Can Dermaseb interact with topical cosmetics or moisturizers?

A: The official interaction profile lists chemical incompatibility with silver preparations and notes factors related to systemic absorption with certain drugs. The profile does not explicitly mention interactions with foods, dietary supplements, topical cosmetics, or common moisturizers.

Q: Is Dermaseb meant to cure the condition, or just manage the symptoms?

A: The general purpose is to control bacterial proliferation and mitigate inflammation. It functions as a bacteriostatic agent, which is described as limiting growth rather than serving as an eradication agent.

Q: What happens if Dermaseb gets into my eyes or mouth?

A: Topical (cutaneous) preparations are strictly labeled as not for ophthalmic use, meaning they should not be applied to the eye. For the ophthalmic preparation, official instructions require the product to be discarded if it darkens in color upon standing.

Q: Why does the official leaflet say Dermaseb is only for people above a certain age?

A: Regulatory documents state that the safety and effectiveness of the topical forms have not been established in children under 12 years of age. This means there is limited or no data available to support use in this younger population.

Q: Is Dermaseb a generic medicine, or does it only come as a brand name?

A: The active ingredient is known chemically as Sulfacetamide (or Sulfacetamide Sodium), which is a synthetic compound. Dermaseb is the name given to the pharmaceutical preparation containing this active ingredient.

Q: Can Dermaseb be used for ringworm on the scalp (tinea capitis)?

A: Dermaseb is classified as an antibacterial agent and is not explicitly defined as a treatment for ringworm (tinea), which is a fungal infection. Its action is focused on bacterial control.

Q: What evidence is there that Dermaseb works better than a placebo?

A: Studies on Dermaseb for short-term symptom changes in rosacea included randomized controlled trials (RCTs) conducted against a vehicle (an inactive agent or placebo) to assess its performance.

Q: What is the difference between the 'How it works' section and the actual mechanism of action?

A: Official documents describe the mechanism through two primary domains: the Antagonism of Microbial Folate Synthesis, which is a process that affects microbial growth, and the Modulation of Inflammatory Mediator Cascades, which is described as relating to host tissue response.

Q: Are there any known long-term side effects associated with Dermaseb use?

A: Official research notes that long-term effects are not fully established across all approved indications. Regulatory documents classify potential outcomes, ranging from common local effects to rare, severe systemic reactions like Stevens-Johnson Syndrome (SJS), a risk associated with the sulfonamide class.

Q: Are there any foods or dietary supplements that interact with Dermaseb?

A: The official interaction profile identifies restrictions with silver preparations and notes population-specific factors related to renal impairment. The profile does not list interactions with foods or dietary supplements.

How should Dermaseb be stored and disposed of?

How to Store and Dispose of Dermaseb

Official regulatory labeling dictates specific conditions for storing and disposing of Dermaseb (Sulfacetamide Sodium/Sulfur topical preparations).


Storage Requirements

Mandatory Storage: Store the product at Controlled Room Temperature (20 to 25 C or 68 to 77 F). The container must be kept tightly closed.

Prohibited Conditions: It is mandatory to protect Dermaseb from freezing and excessive heat. For liquid forms, shake well before using.

Stability Note: The medicine must be kept out of the reach of children. Slight discoloration on storage does not impair the product's efficacy or safety.


Disposal

Disposal of unused or expired product must be done in accordance with local regulation.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dermaseb found in:

A-Z Index: